Efficacy of trabectedin for the treatment of liposarcoma

Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study

(2016) Fernando A. Angarita et al.   BMC CANCER

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

(2016) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Trabectedin is an effective second-line treatment in soft tissue sarcoma patients: Table 1.

(2015) C. Peugniez et al.   ANNALS OF ONCOLOGY

The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma

(2015) Yunfei Liao et al.   CANCER AND METASTASIS REVIEWS

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies

(2015) Margaret von Mehren et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

(2015) B. Bui-Nguyen et al.   EUROPEAN JOURNAL OF CANCER

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

(2015) Akira Kawai et al.   LANCET ONCOLOGY

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial

(2015) Axel Le Cesne et al.   LANCET ONCOLOGY

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

(2015) Patricia Pautier et al.   LANCET ONCOLOGY

Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)

(2015) Bernd Kasper et al.   Marine Drugs

Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics

(2015) V. H. Le et al.   NATURAL PRODUCT REPORTS

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

(2014) M D’Incalci et al.   BRITISH JOURNAL OF CANCER

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies

(2014) Jean-Pascal Machiels et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

(2014) Jean-Yves Blay et al.   EUROPEAN JOURNAL OF CANCER

Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma

(2014) Takafumi Ueda et al.   INVESTIGATIONAL NEW DRUGS

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

(2013) A L Cesne et al.   BRITISH JOURNAL OF CANCER

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification

(2013) Christopher D M Fletcher   HISTOPATHOLOGY

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors

(2013) Cristiana Sessa et al.   INVESTIGATIONAL NEW DRUGS

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

(2013) Mark A. Dickson et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors

(2012) Meredith K. Chuk et al.   PEDIATRIC BLOOD & CANCER

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

(2011) A. Gronchi et al.   ANNALS OF ONCOLOGY

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action

(2011) Jordi Martínez-Serra et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies

(2011) Lia Gore et al.   INVESTIGATIONAL NEW DRUGS

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

(2010) Q. Chu et al.   CLINICAL CANCER RESEARCH

Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors

(2010) Laura Vidal et al.   INVESTIGATIONAL NEW DRUGS

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

(2010) Luis Paz-Ares et al.   INVESTIGATIONAL NEW DRUGS

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

(2009) B. Forouzesh et al.   CLINICAL CANCER RESEARCH

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours

(2009) C. Sessa et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

(2009) C. Forni et al.   MOLECULAR CANCER THERAPEUTICS

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

(2008) M. von Mehren et al.   ANNALS OF ONCOLOGY

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

(2008) Wells A. Messersmith et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma

(2008) J.-Y. Blay et al.   CLINICAL CANCER RESEARCH

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer

(2008) C. Sessa et al.   EUROPEAN JOURNAL OF CANCER

Transcription-coupled DNA Double-Strand Breaks Are Mediated via the Nucleotide Excision Repair and the Mre11-Rad50-Nbs1 Complex

(2008) Josée Guirouilh-Barbat et al.   MOLECULAR BIOLOGY OF THE CELL